Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03596242 · ClinicalTrials.gov registry record · NA

SMS System for Patients With Uncontrolled Hypertension

A NA study, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
NA
Development phase
24
Enrollment target

NCT03596242: Completed NA study, sponsored by Wake Forest University Health Sciences.

NCT03596242 is a NA study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03596242, a NA study, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target

Study Summary

This is a pilot study to determine the potential of utilizing Short Message Service (SMS) messaging to improve health outcomes for patients with uncontrolled hypertension receiving care from the Outpatient Internal Medicine Clinic at Wake Forest Baptist Hospital.

Interventions

  • OTHER SMS System
  • BEHAVIORAL blood pressure control education

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2021-03-09
Est. Completion 2021-12-06
Phase NA
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT03596242 record still lists

NCT03596242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 2 interventions - of which SMS System is the first listed.

NCT03596242 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03596242 about?

NCT03596242 is a clinical study titled "SMS System for Patients With Uncontrolled Hypertension". This is a pilot study to determine the potential of utilizing Short Message Service (SMS) messaging to improve health outcomes for patients with uncontrolled hypertension receiving care from the Outpatient Internal Medicine Clinic at Wake Forest Baptist Hospital.

What is the current status of trial NCT03596242?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2021-03-09. Estimated completion is 2021-12-06.

What interventions are being tested in trial NCT03596242?

The interventions under investigation include: SMS System (OTHER), blood pressure control education (BEHAVIORAL).

Who is sponsoring clinical trial NCT03596242?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03596242's enrollment target sits among peer trials

24 1736th of 2000 higher than 246 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03596242, the US trial registry maintained by the National Library of Medicine. NCT03596242 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.